Ipilimumab/Nivolumab versus Lenvatinib/Pembrolizumab in Ras-Mutated Anaplastic Thyroid Cancer

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Lenvima (lenvatinib) - Eisai, Merck (MSD)

Keytruda (pembrolizumab) - Merck (MSD)

Ipilimumab/Nivolumab versus Lenvatinib/Pembrolizumab in Ras-Mutated Anaplastic Thyroid Cancer (ATA 2026) - Sep 19, 2026 - Abstract #P588; Pres time: Nov 6, 2026; 02:15 PM - 03:15 PM; No abstract available
Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • RAS

https://thyroid.joynmeeting.com/conference_hall/server/poster_schedule.php

Alanoud Alaasmi; Sualeha Khalid; Anna Lawless; Victoria Banuchi; Maria Cabanillas; Ramona Dadu; Isabelle Fournier; Maria Gule-Monroe; Brandon Gunn; Priyanka Iyer; Anna Lee; Anastasios Maniakas; Michael Spiotto; Jainy Thomas; Rui Jennifer Wang; Mark Zafereo; Naifa Busaidy; Sarah Hamidi

Sep 19, 2026